Skip to Content
Søk Menu
Sara Tolaney

ASCO 2025: Redefining First-Line Therapy in HER2+ Breast Cancer with T-DXd and Pertuzumab

/ Sara Tolaney
ASCO25BröstcancerNBCN Play the Video
Ioannis Zerdes

Multidimensional Profiling of Immune Micro- and Macro-Environment in Early Breast Cancer Treated with Neoadjuvant Therapy

/ Ioannis Zerdes
BröstcancerNBCN Play the Video
Irma Frederiksson & Tove Filtenborg Tvedskov

Clinical Controversies in Axillary Management in Breast Cancer

/ Irma Frederiksson / Tove Holst Filtenborg Tvedskov
BröstcancerNBCN Play the Video
Tobias Berg

Increased Need for Improvement in the Treatment of Non-Luminal A Subtype Metastatic Breast Cancer in First-Line Treatment

/ Tobias Berg
BröstcancerNBCN Play the Video
Kristine Wiborg Høgsbjerg

Boost vs Surgery: Breast Induration Risk

/ Kristine Wiborg Høgsbjerg
Bröstcancer Play the Video
Per Hall

Making Primary Breast Cancer Prevention a Reality

/ Per Hall
Bröstcancer Play the Video
Philip Poortmans

Breast Cancer Treatment: The Role of Boost Radiation Therapy in Reducing Recurrence Risks

/ Philip Poortmans
BröstcancerOnkologisk Forum 2024 Play the Video
Demet Özcan

Breast Cancer: The Prognostic Value of Tumor-Infiltrating Lymphocytes

/ Demet Özcan
BröstcancerSABCS24 Play the Video
Hope Rugo

Abemaciclib Shows Significant Benefit for HR-Positive HER2-Negative Patients with Advanced Breast Cancer

/ Hope S. Rugo
Bröstcancer Play the Video
Maren Marie Andreassen

MRI-Based AI Can Detect Responsive Treatment of Breast Cancer After Three Weeks of Therapy

/ Maren Marie Andreassen
BröstcancerNBCN Play the Video
Adam Brufsky

SABCS 2024: Palbociclib, Abemaciclib, and Ribociclib Can Be Considered Equivalent in the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

/ Adam Brufsky
BröstcancerSABCS24 Play the Video
Stefania Katrin Finnsdottir

The Need to Improve Compliance with Adjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer

/ Stefanía Katrín Finnsdóttir
BröstcancerNBCN Play the Video
Hent flere
Back to top